The P2X7 Receptor as a Mechanistic Biomarker for Epilepsy
Author:
Open Access
- 12 March 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5410
Abstract
Epilepsy, characterized by recurrent spontaneous seizures, is a heterogeneous group of brain diseases affecting over 70 million people worldwide. Major challenges in the management of epilepsy include its diagnosis and treatment. To date, video electroencephalogram (EEG) monitoring is the gold-standard diagnostic method, with no molecular biomarker in routine clinical use. Moreover, treatment based on anti-seizure medications (ASMs) remains ineffective in 30% of patients, and, even if seizure-suppressive, lacks disease-modifying potential. Current epilepsy research is, therefore, mainly focussed on the identification of new drugs with a different mechanism of action effective in patients not responding to current ASMs. The vast heterogeneity of epilepsy syndromes, including differences in underlying pathology, comorbidities and disease progression, represents, however, a particular challenge in drug discovery. Optimal treatment most likely requires the identification of new drug targets combined with diagnostic methods to identify patients in need of a specific treatment. Purinergic signalling via extracellularly released ATP is increasingly recognized to contribute to brain hyperexcitability and, consequently, drugs targeting this signalling system have been proposed as a new therapeutic strategy for epilepsy. Among the purinergic ATP receptors, the P2X7 receptor (P2X7R) has attracted particular attention as a novel target for epilepsy treatment, with P2X7Rs contributing to unresponsiveness to ASMs and drugs targeting the P2X7R modulating acute seizure severity and suppressing seizures during epilepsy. In addition, P2X7R expression has been reported to be altered in the brain and circulation in experimental models of epilepsy and patients, making it both a potential therapeutic and diagnostic target. The present review provides an update on the newest findings regarding P2X7R-based treatments for epilepsy and discusses the potential of P2X7R as a mechanistic biomarker.Keywords
Funding Information
- Science Foundation Ireland (17/CDA/4708, 16/RC/3948)
- European Regional Development Fund (17/CDA/4708, 16/RC/3948)
This publication has 154 references indexed in Scilit:
- Cellular function and molecular structure of ecto-nucleotidasesPurinergic Signalling, 2012
- Temporal Lobe Epilepsy SemiologyEpilepsy Research and Treatment, 2012
- The P2X7 receptor–pannexin-1 complex decreases muscarinic acetylcholine receptor–mediated seizure susceptibility in miceJournal of Clinical Investigation, 2011
- P2X7 receptor regulates leukocyte infiltrations in rat frontoparietal cortex following status epilepticusJournal of Neuroinflammation, 2010
- P2X7 receptor differentially modulates astroglial apoptosis and clasmatodendrosis in the rat brain following status epilepticusHippocampus, 2010
- P2X7-Dependent Release of Interleukin-1β and Nociception in the Spinal Cord following LipopolysaccharideJournal of Neuroscience, 2010
- ABC transporters: the power to changeNature Reviews Molecular Cell Biology, 2009
- Identification of a vesicular nucleotide transporterProceedings of the National Academy of Sciences, 2008
- New insights into purinergic receptor signaling in neuronal differentiation, neuroprotection, and brain disordersPurinergic Signalling, 2007
- The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role.Journal of Clinical Investigation, 1995